SARS-CoV-2 is transmitted through airborne droplets and tiny particles, making the respiratory system its primary route of infection. Researchers use this to their advantage by designing inhalable drugs comprised of tiny antibodies that protect against SARS-CoV-2. This webinar will explore the world of small, inhalable antibodies and how scientists use this new approach to guard against SARS-CoV-2 infection.

Topics to be covered

-Aerosolized nanobodies for SARS-CoV-2 passive immunization
-Multivalent nanobodies from llamas efficiently neutralize SARS-CoV-2

  • 1614710745-269a5134694eb8b4
    Aashish Manglik, MD, PhD
    Assistant Professor, Department of Pharmaceutical Chemistry, University of California San Francisco
    Aashish Manglik investigates how cells sense and respond to their external environment. His research team studies the largest family of receptors in the genome that interpret thousands of cellular communication signals and allows humans to see, smell, and taste. With deep insight into how these receptors work, Manglik’s team develops ways to precisely control cell signaling to tackle diseases ranging from cancer to depression. Manglik received his bachelor's degree from Washington University in St. Louis where he trained as a chemist and earned a dual MD and PhD at Stanford University in 2016. Manglik established his independent laboratory as the inaugural Stanford Distinguished Fellow in 2016 and joined the faculty at the University of California, San Francisco in 2017 as an assistant professor. Manglik has received the Early Independence Award, the Pew Biomedical Scholars Award, the Simons-Klingenstein Fellowship, and the Kinship Foundation, Searle Scholars Award.
  • 1614710822-3dc821ec609b2167
    Yi Shi, PhD
    Assistant Professor, Department of Cell Biology, Program for Integrative Systems Biology, Carnegie Mellon University-Pitt Program in Computational Biology, University of Pittsburgh School of Medicine
    Yi Shi earned his PhD in biochemistry and molecular biology from Baylor College of Medicine and completed a postdoctoral fellowship in Mass Spectrometry and Proteomics at The Rockefeller University. In 2017, he joined the Department of Cell Biology at the University of Pittsburgh School of Medicine as an assistant professor. Shi’s research group develops cutting-edge proteomic technologies for basic biological research and human diseases, such as aging and neurodegenerative disorders. Using a combination of proteomics, cell biology, and biophysics, Shi’s team elucidates the structure and function of large native macromolecular assemblies and dissects biological pathways that regulate autophagy and aging. Shi’s research group is also at the forefront of cutting-edge nanobody-based technologies. Shi uses these technologies to develop solutions to the ongoing SARS-CoV-2 pandemic.